m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG04124)
Name
Stenoparib
Status
Phase 2
TTD Drug ID
DP48WE
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Poly [ADP-ribose] polymerase 1 (PARP1)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for Stenoparib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Stenoparib through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). [1], [2]
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for Stenoparib. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Stenoparib through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). [1], [2]
Tankyrase-1 (TNKS-1)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Tankyrase-1 (TNKS-1) is a therapeutic target for Stenoparib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Stenoparib through regulating the expression of Tankyrase-1 (TNKS-1). [3], [4]
References
Ref 1 METTL3 promotes oxaliplatin resistance of gastric cancer CD133+?stem cells by promoting PARP1 mRNA stability. Cell Mol Life Sci. 2022 Feb 18;79(3):135. doi: 10.1007/s00018-022-04129-0.
Ref 2 Inhibition of poly (ADP-ribose) polymerase as a protective effect of nicaraven in ionizing radiation- and ara-C-induced cell death. Anticancer Res. 2006 Sep-Oct;26(5A):3421-7.
Ref 3 Upregulated METTL3 in nasopharyngeal carcinoma enhances the motility of cancer cells. Kaohsiung J Med Sci. 2020 Nov;36(11):895-903. doi: 10.1002/kjm2.12266. Epub 2020 Jul 15.
Ref 4 Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc Natl Acad Sci U S A. 2012 Jul 17;109(29):11717-22. doi: 10.1073/pnas.1120068109. Epub 2012 Jul 2.